1	
2	Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced
3 ⊿	immunity in older adults
4 5	Janna R. Shapiro ¹ , Han-Sol Park ² , Tihitina Y. Aytenfisu ³ , Christopher Caputo ² , John Lee ² , Trevor
6	S. Jonnston ² , Hulfen Ll ² , Priclia Hauk ² , Henning Jacobsen ² , Yukang Ll ² , Engle Abrams ³ , Andrew J.
/	Kocot ² , Hanrul Yang ² , Yushu Huang ² , Steven M. Cramer ² , Michael J. Betenbaugh ² , Amanda K.
8 0	Debes-, Rosemary Morgan-, Aaron M. Milstone ⁷⁷ , Andrew H. Karaba ⁵ , Sean X. Leng ^{-, 77} , and
9 10	Sabra L. Kielii-
11	¹ Department of International Health, Johns Honkins Bloomberg School of Public Health
12	Baltimore, MD, USA.
13 14	² W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
15	³ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
16 17	⁴ Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
18	⁵ Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Trov
19	NY, US
20 21	Department of Chemical and Biomolecular Engineering, Johns Hopkins Whiting School of Engineering, Baltimore, MD, USA
22	⁷ Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
23 24	⁸ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD_USA
25	⁹ Johns Hopkins Center on Aging and Immune Remodeling, Baltimore, MD, USA
26	
27 28	Key words: antibody response, ACE2, sex differences, Delta, Omicron
29	Running title: COVID-19 vaccination in older adults
30	Manuscript statistics:
31	Abstract: 248
32	Main text: 3233
33	Figure: 5
34	Tables: 2
35	References: 49
36	
37	Contact information: Address correspondence to Sabra L. Klein (<u>sklein2@jhu.edu</u>) or Sean X.
38	Leng (<u>sleng1@jhmi.edu</u>)
39	
40	Brief summary: SARS-CoV-2 mRNA vaccination induces greater antibody response in older
41	females than males, and age and frailty reduce responses in males only. These effects are
42 43 44	eliminated by a third vaccine dose, highlighting the need for third dose coverage, especially in older males.
••	

Shapiro et al. 2

45 Abstract

46	Background: Male sex and old age are risk factors for severe COVID-19, but the intersection of
47	sex and aging on antibody responses to SARS-CoV-2 vaccines has not been characterized.
48	Methods: Plasma samples were collected from older adults (75-98 years) before and after
49	three doses of SARS-CoV-2 mRNA vaccination, and from younger adults (18-74 years) post-dose
50	two, for comparison. Antibody binding to SARS-CoV-2 antigens (spike protein [S], S-receptor
51	binding domain [S-RBD], and nucleocapsid [N]) and functional activity against S were measured
52	against the vaccine virus and variants of concern (VOC).
53	Results: Vaccination induced greater antibody titers in older females than males, with both age
54	and frailty associated with reduced antibody responses to vaccine antigens in males, but not
55	females. ACE2 binding inhibition declined more than anti-S or anti-S-RBD IgG in the six months
56	following the second dose (28-fold vs. 12- and 11-fold decreases in titer). The third dose
57	restored functional antibody responses and eliminated disparities caused by sex, age, and
58	frailty in older adults. Responses to the VOC were significantly reduced relative to the vaccine
59	virus, with older males having lower titers to the VOC than females. Older adults had lower
60	responses to the vaccine and VOC viruses than younger adults, with disparities being greater in
61	males than females.
62	Conclusion: Older and frail males may be more vulnerable to breakthrough infections due to
63	low antibody responses before receipt of a third vaccine dose. Promoting third dose coverage

64 in older adults, especially males, is crucial to protecting this vulnerable population.

Shapiro et al. 3

65 Introduction

66	The disproportionate burden of COVID-19 in older adults was recognized early in the
67	pandemic [1-3]. The phase III trials for the two mRNA vaccines (mRNA-1273 and BNT162b2)
68	revealed high efficacy in older adults [4, 5], for whom immunosenescence is thought to impair
69	vaccine-induced immune responses [6]. Clinical trials, however, often fail to represent the
70	oldest and frailest subset of the population. Accordingly, wide-spread use of the vaccine in
71	long-term care facility residents revealed that old age is a risk factor for poor antibody
72	responses [7-9].
73	Male sex also is a significant predictor of severe COVID-19 outcomes at older ages [10-
74	14]. There is extensive evidence that the effects of aging on the immune system differ between
75	the sexes, including that immunosenescence occurs at a slower rate in females than males [15,
76	16]. The implications of biological sex are evident in the response to repeated seasonal
77	influenza vaccination in older adults, where pre-vaccination titers decrease with age in males
78	but not in females, suggesting that older females enter each influenza season with greater
79	immunity than their male counterparts [17]. In the context of SARS-CoV-2 vaccines, however,
80	studies have failed to provide sex-disaggregated data within each age group [18, 19], and little
81	is known about how biological sex may modify the effects of age, and age-related factors like
82	frailty, on vaccine immunogenicity. Here, we investigate sex differences and sex-specific effects
83	of aging in the humoral immune response to the vaccine virus and variants of concern (VOC)
84	induced by three doses of a SARS-CoV-2 mRNA vaccine in a cohort of adults above 75 years of
85	age. We illustrate that the age- and frailty-associated declines in antibody responses occur to a
86	greater extent in males than females.

87	
88	Methods
89	Cohorts
90	Older adults (75-98 years) were recruited from the Johns Hopkins Longitudinal Influenza
91	Immunization Study of Aging over 75 years of age (JH LIISA 75+) cohort [17] (Table 1).
92	Individuals who had worsening or new-onset of immune-modulating conditions (e.g.,
93	rheumatoid arthritis, hematologic malignancies, or other cancers) or a previous diagnosis of
94	COVID-19 were excluded. Participants came to the Johns Hopkins Bayview Medcal Center, or
95	study visits were conducted at participants' homes, as needed. At pre-vaccination visits (Pre),
96	frailty status was assessed using the Fried Frailty Phenotype [20] and a baseline blood draw was
97	obtained. Subsequent receipt of two (primary vaccination series) or three doses of a SARS-CoV-
98	2 mRNA vaccine, either mRNA-1273 or BNT162b2, was confirmed via vaccination cards, and
99	blood samples were collected 14-30 days (i.e., average ≤ 1 month [M]) post dose 1 (<1M_PD1)),
100	14-30 days post dose 2 (<1M_PD2), 90 (± 15) days post dose 2 (3M_PD2), 180 (± 15) days post
101	dose 2 (6M_PD2), and 14-60 days post dose 3 (1M_PD3).
102	Younger adult healthcare workers from the Johns Hopkins Health System were also
103	sampled as a comparison group. Recruitment of these younger adults has been reported
104	elsewhere [21]. To be eligible for the present study, participants needed to be younger than 75
105	years, not have a history of COVID-19, and have two samples collected at least 90 days apart,
106	with the first one collected at least 14 days after receiving the second dose of a SARS-CoV-2
107	mRNA vaccine. Due to low plasma volumes, these amples were not tested for ACE2-inhibition,
108	and data are missing for antibody titration against antigens from VOC for some participants.

Shapiro et al. 5

- 109 Exact sample sizes are included in figure legends. For both cohorts, written, informed consent
- 110 was obtained from all participants, and the study protocols were approved by the Johns
- 111 Hopkins School of Medicine Institutional Review Board.
- 112

113 Laboratory methods

114 Detailed ELISA and ACE2 inhibition methods can be found in the **Supplemental**

115 materials. Briefly, plasmids expressing recombinant nucleocapsid (N), Spike (S), or S receptor-

binding domain (S-RBD) of the vaccine strain and the Alpha, Delta, and Omicron variants of

117 SARS-CoV-2 were engineered at Johns Hopkins as described previously [22] or obtained through

the NCI Serological Sciences Network for COVID-19 [23] (Supplemental Table 1). Recombinant

119 proteins were used to coat plates for indirect ELISA measuring plasma IgG against N, S, or S-

120 RBD. Results were expressed as the log₁₀-transformed area under the curve (AUC) generated

121 from ten three-fold serial plasma dilutions, as previously described [22]. The ability of plasma

122 antibodies to inhibit ACE2 binding to S was measured using Meso Scale Diagnostics (MSD) V-

123 PLEX SARS-CoV-2 ACE2 kits according to the manufacturer's protocol at a dilution of 1:100 [24].

124 Data were expressed as the log_{10} -transformed concentration ($\mu g/ml$) of ACE2-inhibiting

125 antibodies (ACE2iAb), which are equivalent to anti-S monoclonal antibodies. IgG binding to

126 seasonal and epidemic β-coronavirus S proteins were measured using the multiplex

127 chemiluminescent MSD V-PLEX COVID-19 Coronavirus Panel 3 (IgG) Kit according to the

128 manufacturer's protocol at a dilution of 1:5000.

129

Shapiro et al. 6

130 Statistical methods

131	Longitudinal data in the older adult cohort were analyzed using mixed-effects models
132	with random intercepts on the individual to account for repeated measures, and interaction
133	terms between study timepoint (categorical) and sex (self-report), age (categorized based on
134	terciles) and frailty status. Linear regression models including interaction terms between sex
135	and age or frailty were used to investigate sex-specific effects at individual timepoints. To
136	compare the older and younger cohorts, the number of days post-dose 2 was used as a
137	continuous predictor and cubic splines were included to study non-linear relationships [25].
138	Cubic spline knots were placed at 30-, 100-, and 160-days post-vaccination, points chosen to
139	approximately divide the data into quartiles. Mixed-effects models included an interaction term
140	between time and cohort and were repeated separately for males and females. Differences
141	between cohorts were tested at three sentinel points (14-, 90- and 180- days post dose 2). All
142	p-values <0.05 were considered statistically significant. Analyses were performed in Stata 15
143	(StataCorp).

144

145 <u>Results</u>

146 **Study population demographics**

Eighty-six older adults were recruited from the Baltimore area, with three participants excluded from analysis due to high N titers (i.e., titer >180), suggesting prior infection (Supplemental figure 1). One additional participant was excluded from analysis due to evidence of severe immunosuppression, such that their responses could not be accurately captured in population-level models. Characteristics of the 82 participants included in analysis are detailed

152	in Table 1 . The population had more females (59%) than males, and a median age of 84 years.
153	Most participants were classified as pre-frail (64%) and a greater percentage of males than
154	females were frail. All participants received two doses of a SARS-CoV-2 mRNA vaccine, with the
155	majority (70%) receiving BNT162b2. Sixty participants (73%) received a third vaccine dose at
156	least six months after the second dose.
157	Demographic information for the younger adult cohort is provided in Table 2 . Of 84
158	eligible participants from the affiliated study [21], three were excluded due to high anti-N titers
159	(Supplemental figure 1). In the younger population included in analysis, there were more
160	females than males (60% vs 40%), most participants were between 30 and 49 years of age, and
161	a majority of samples were collected 21-43 days and 125-150 days after receipt of the second
162	vaccine dose.
162	
105	
164	Older females mount greater responses to vaccination than older males
164 165	Older females mount greater responses to vaccination than older males Among older adults, IgG binding to S and S-RBD of the vaccine strain increased
163 164 165 166	Older females mount greater responses to vaccination than older males Among older adults, IgG binding to S and S-RBD of the vaccine strain increased significantly in response to the first two vaccine doses and then decreased significantly in the 6
163 164 165 166 167	Older females mount greater responses to vaccination than older males Among older adults, IgG binding to S and S-RBD of the vaccine strain increased significantly in response to the first two vaccine doses and then decreased significantly in the 6 months following immunization (p<0.001 for all comparisons; Figure 1A-B & D). Geometric
163 164 165 166 167 168	Older females mount greater responses to vaccination than older males Among older adults, IgG binding to S and S-RBD of the vaccine strain increased significantly in response to the first two vaccine doses and then decreased significantly in the 6 months following immunization (p<0.001 for all comparisons; Figure 1A-B & D). Geometric mean titers (GMT) decreased 11- and 12-fold, for S and S-RBD, respectively, from <1M_PD2 to
163 164 165 166 167 168 169	Older females mount greater responses to vaccination than older males Among older adults, IgG binding to S and S-RBD of the vaccine strain increased significantly in response to the first two vaccine doses and then decreased significantly in the 6 months following immunization (p<0.001 for all comparisons; Figure 1A-B & D). Geometric mean titers (GMT) decreased 11- and 12-fold, for S and S-RBD, respectively, from <1M_PD2 to 6M_PD2 (Supplemental Table 2). Females mounted greater IgG responses to S and S-RBD
163 164 165 166 167 168 169 170	Older females mount greater responses to vaccination than older males Among older adults, IgG binding to S and S-RBD of the vaccine strain increased significantly in response to the first two vaccine doses and then decreased significantly in the 6 months following immunization (p<0.001 for all comparisons; Figure 1A-B & D). Geometric mean titers (GMT) decreased 11- and 12-fold, for S and S-RBD, respectively, from <1M_PD2 to 6M_PD2 (Supplemental Table 2). Females mounted greater IgG responses to S and S-RBD relative to their baseline than males at all post-vaccination timepoints (p<0.02 for all
163 164 165 166 167 168 169 170 171	Older females mount greater responses to vaccination than older males Among older adults, IgG binding to S and S-RBD of the vaccine strain increased significantly in response to the first two vaccine doses and then decreased significantly in the 6 months following immunization (p<0.001 for all comparisons; Figure 1A-B & D). Geometric mean titers (GMT) decreased 11- and 12-fold, for S and S-RBD, respectively, from <1M_PD2 to 6M_PD2 (Supplemental Table 2). Females mounted greater IgG responses to S and S-RBD relative to their baseline than males at all post-vaccination timepoints (p<0.02 for all comparisons, Figure 1A-B & D). Older females also had greater titers of IgG against S and S-RBD
163 164 165 166 167 168 169 170 171 172	Older females mount greater responses to vaccination than older males Among older adults, IgG binding to S and S-RBD of the vaccine strain increased significantly in response to the first two vaccine doses and then decreased significantly in the 6 months following immunization (p<0.001 for all comparisons; Figure 1A-B & D). Geometric mean titers (GMT) decreased 11- and 12-fold, for S and S-RBD, respectively, from <1M_PD2 to 6M_PD2 (Supplemental Table 2). Females mounted greater IgG responses to S and S-RBD relative to their baseline than males at all post-vaccination timepoints (p<0.02 for all comparisons, Figure 1A-B & D). Older females also had greater titers of IgG against S and S-RBD at each visit, and this difference was significant for anti-S IgG at <1M_PD1 (p=0.020) and at

Shapiro et al. 8

174	significantly in both males and females (p<0.001), leading to GMT that were 2- and 4-fold
175	greater than the post-dose 2 peak for S and S-RBD, respectively (Supplemental Table 2).
176	The functional ability of antibodies to inhibit S from binding to ACE2 followed similar
177	kinetics as anti-S IgG in response to the primary immunization series, but then decreased more
178	rapidly in the 6-months following immunization, resulting in a 28-fold decrease in GMT from
179	<1M_PD2 to 6M_PD2 (Figure 1C & Supplemental Table 2). By 6M_PD2, 79% of males and 77%
180	of females had undetectable ACE2iAb. Sex differences were apparent at all timepoints and
181	were significant at 3M_PD2, with females mounting stronger responses than males (p=0.046).
182	Post dose 3, all but one participant had detectable ACE2iAb, and the geometric mean was 7-
183	fold higher than the post-dose 2 peak (Supplemental Table 2). Despite differences in kinetics
184	over time between the binding and functional assays, the three readouts of humoral immunity
185	correlated well with each other (Supplemental figure 2). As expected, correlations became
186	weaker at the lower range of the ACE2-inhibition assay. Taken together, these data suggest that
187	older females mount stronger response to SARS-CoV-2 vaccination than males, and that a third
188	vaccine dose is necessary to boost functional antibody responses in this population.
189	
190	The effects of age and frailty are greater in males than in females
191	We next assessed the overall and sex-specific effects of age on the humoral response to
192	vaccination. Among all older participants, age was significantly associated with reduced anti-S
193	IgG, anti-S-RBD IgG, and ACE2iAb in the six months following the primary vaccination series
194	(Figure 2A-C). This effect was largely driven by the oldest tercile of the population (≥88 years).

195 The percent of participants with undetectable ACE2iAb by 6M_PD2 increased from 67% in the

Shapiro et al. 9

196	youngest tercile (75-82 years) to 85% in the oldest tercile. In sex-disaggregated analyses
197	focusing on the 3M_PD2 timepoint (i.e., a time point when all study participants were
198	represented), age significantly impaired responses in males, but not females, leading to
199	statistically significant sex differences in the effect of age for anti-S IgG (p=0.025) and ACE2iAb
200	(p = 0.001; Figure 2D-F). The trend of greater age effects in males than females was consistent
201	at other timepoints following the primary immunization series (Supplemental figure 3A-F), and
202	by 6M_PD2, 100% of males in the oldest age group, compared to 77% of females, had
203	undetectable ACE2iAB. After receipt of a third dose, the effect of age was no longer significant
204	in the overall population or within either sex, suggesting that a third vaccine dose eliminated
205	sex and age disparities in vaccine-induced immunity (Figure 2A-C & Supplemental figure 3G-I).
206	Frailty had an important overall effect, with frail participants mounting significantly
207	weaker responses to vaccination than robust and pre-frail participants (Figure 2G-I). By
208	6M_PD2, 90% of frail participants had undetectable ACE2iAb, compared to 75% of pre-frail and
209	robust participants. Like with age, the effect of frailty at 3M_PD2 was significant in males, but
210	not females for all assays (Figure 2J-L). No significant sex differences in the effect of frailty were
211	observed, however, and trends were less consistent over time (Supplemental figure 3J-R). The
212	effect of frailty was also attenuated by the third dose but remained significant for ACE2iAb
213	(p=0.005; Figure 2I). From these data, we conclude that the effects of age and frailty in older
214	adults are largely driven by males, not females.

215

Shapiro et al. 10

216 Antibody responses to VOC are reduced relative to the vaccine virus

217 The breadth of vaccine-induced immunity in older adults was assessed by measuring 218 anti-S IgG to the Alpha, Delta, and Omicron variants. Antibody titers to the Alpha and Delta 219 variants were similar to each other and were both significantly reduced relative to the vaccine 220 virus (2-4-fold lower GMT, p<0.001; Figure 3A & Supplemental Table 3). Titers to Omicron were 221 further reduced relative to the vaccine virus (>5-fold difference in GMT) and the Alpha and 222 Delta variants (p<0.001 for all comparisons; Figure 3A & Supplemental Table 3). Differences 223 between anti-S IgG to the vaccine virus and the VOC were attenuated at 1M PD3 (fold 224 difference in GMT <1.5 for Alpha and Delta and <4 for Omicron) but remained significant 225 (p<0.0001 for all comparisons). At 1M PD3, anti-Alpha S IgG was significantly higher than anti-226 Delta S IgG (p<0.001). ACE2iAb to the Alpha and Delta variants also tended to be lower than to 227 the vaccine strain, but these differences were smaller in magnitude than for anti-S IgG and 228 were not statistically significant at all timepoints (Figure 3B-C). In sex-disaggregated analyses, 229 females had higher responses to the VOC than males, and this difference was significant for 230 anti-Delta S IgG (p=0.038) and ACE2iAb against the Alpha variant (p=0.034) at 3M PD2 (Figure 231 **3D-E & Supplemental figure 4).** 232

233 SARS-CoV-2 vaccination induces IgG responses to other β-coronaviruses

To investigate the crosss-reactivity of the vaccine-induced humoral response, IgG titers
to seasonal and epidemic β-coronaviruses were measured in the older adults. Anti-HKU1 IgG
titers increased in response to the primary vaccination series, but fell by 3M_PD2 (Figure4A).
Titers of IgG recognizing OC43, MERS-CoV, and SARS-CoV-1 increased significantly in plasma

238	samples collected after SARS-CoV-2 vaccination and remained elevated above baseline levels
239	for 6 months (Figure 4B-D). Furthermore, titers to all four β -coronaviruses were significantly
240	elevated by the third vaccine dose (Figure 4A-D). Notably, IgG binding to the two seasonal eta -
241	coronaviruses (HKU1 and OC43) was elevated at baseline, indicating widespread exposure to
242	these viruses in this population. Increased antibody titers against related eta -coronaviruses
243	following SARS-CoV-2 vaccination suggests possible "back-boosting", as observed for influenza
244	vaccines [26] and in response to SARS-CoV-2 vaccination in the general adult population [27,
245	28]. These results indicate that SARS-CoV-2 vaccination increases broad antibody responses to
246	diverse β-coronaviruses in older adults.
247	
248	Differences between older and younger cohorts are driven by males
249	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine,
249 250	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine, Alpha, and Delta antigens were compared between the younger and older adult cohorts in the
249 250 251	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine, Alpha, and Delta antigens were compared between the younger and older adult cohorts in the six months following the primary vaccination series. In the whole population, anti-vaccine S IgG
249 250 251 252	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine, Alpha, and Delta antigens were compared between the younger and older adult cohorts in the six months following the primary vaccination series. In the whole population, anti-vaccine S IgG was significantly lower in older than younger adults (p<0.001 at 14 days post-vaccination,
249 250 251 252 253	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine, Alpha, and Delta antigens were compared between the younger and older adult cohorts in the six months following the primary vaccination series. In the whole population, anti-vaccine S IgG was significantly lower in older than younger adults (p<0.001 at 14 days post-vaccination, p=0.004 at 90 days, and p=0.026 at 180 days) (Figure 5A). In sex-disaggregated analyses,
249 250 251 252 253 254	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine, Alpha, and Delta antigens were compared between the younger and older adult cohorts in the six months following the primary vaccination series. In the whole population, anti-vaccine S IgG was significantly lower in older than younger adults (p<0.001 at 14 days post-vaccination, p=0.004 at 90 days, and p=0.026 at 180 days) (Figure 5A). In sex-disaggregated analyses, differences between the older and younger adults were significant among males at all three
249 250 251 252 253 254 255	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine, Alpha, and Delta antigens were compared between the younger and older adult cohorts in the six months following the primary vaccination series. In the whole population, anti-vaccine S IgG was significantly lower in older than younger adults (p<0.001 at 14 days post-vaccination, p=0.004 at 90 days, and p=0.026 at 180 days) (Figure 5A). In sex-disaggregated analyses, differences between the older and younger adults were significant among males at all three sentinel points (p=0.004 at 14 days post-vaccination, p=0.005 at 90 days, and p=0.019 at 180
249 250 251 252 253 254 255 256	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine, Alpha, and Delta antigens were compared between the younger and older adult cohorts in the six months following the primary vaccination series. In the whole population, anti-vaccine S IgG was significantly lower in older than younger adults (p<0.001 at 14 days post-vaccination, p=0.004 at 90 days, and p=0.026 at 180 days) (Figure 5A). In sex-disaggregated analyses, differences between the older and younger adults were significant among males at all three sentinel points (p=0.004 at 14 days post-vaccination, p=0.005 at 90 days, and p=0.019 at 180 days), but only significant among females at 14-days post vaccination (p=0.004) (Figure 5B-D).
249 250 251 252 253 254 255 256 257	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine, Alpha, and Delta antigens were compared between the younger and older adult cohorts in the six months following the primary vaccination series. In the whole population, anti-vaccine S IgG was significantly lower in older than younger adults (p<0.001 at 14 days post-vaccination, p=0.004 at 90 days, and p=0.026 at 180 days) (Figure 5A). In sex-disaggregated analyses, differences between the older and younger adults were significant among males at all three sentinel points (p=0.004 at 14 days post-vaccination, p=0.005 at 90 days, and p=0.019 at 180 days), but only significant among females at 14-days post vaccination (p=0.004) (Figure 5B-D). In addition, the magnitude of the difference between the mean of the older cohort and the
249 250 251 252 253 254 255 256 257 258	To further investigate the sex-specific effects of aging, antibody kinetics against vaccine, Alpha, and Delta antigens were compared between the younger and older adult cohorts in the six months following the primary vaccination series. In the whole population, anti-vaccine S IgG was significantly lower in older than younger adults (p<0.001 at 14 days post-vaccination, p=0.004 at 90 days, and p=0.026 at 180 days) (Figure 5A). In sex-disaggregated analyses, differences between the older and younger adults were significant among males at all three sentinel points (p=0.004 at 14 days post-vaccination, p=0.005 at 90 days, and p=0.019 at 180 days), but only significant among females at 14-days post vaccination (p=0.004) (Figure 5B-D). In addition, the magnitude of the difference between the mean of the older cohort and the mean of younger cohort was consistently larger for males than for females across the three

Shapiro et al. 12

- 260 **5E-L**). There were no significant differences in the rate of waning between older and younger
 261 adults, suggesting that antibody kinetics are not age-dependent.
- 262

263 Discussion

264 In this longitudinal study, older adult females mounted stronger antibody responses to SARS-CoV-2 mRNA vaccination than older males, and age and frailty were associated with 265 266 reduced responses in males but not females. While the kinetics of antibody waning in the six 267 months following immunization were not age-dependent, older adults mounted weaker initial 268 responses to vaccination, such that their antibody titers remained lower than younger adults 269 throughout the follow-up period. A sex-specific effect of age was observed both within the 270 older cohort and when comparing younger and older adults, in which age-associated reductions 271 in humoral immunity were greater among males than females. In the older adult cohort, receipt 272 of a third vaccine dose largely eliminated disparities caused by sex, age, and frailty in antibody responses, with the exception of ACE2iAb, which remained lower in frail compared to non-frail 273 274 or pre-frail participants. The effect of age on SARS-CoV-2 vaccine responses has been studied 275 [7-9, 29-33], but the sex differential impact of age has not been reported previously. 276 Furthermore, studies investigating frailty have not found an effect on antibody responses [34-277 36], but have reported that frailty increases the risk of post-vaccination breakthrough infection 278 [37, 38], suggesting that the immunogenicity studies may have been under-powered to observe 279 an effect of frailty or that lack of consideration of biological sex obscured the effect. 280 The inclusion of three measures of humoral immunity and four SARS-CoV-2 viruses 281 allowed us to capture the breadth and depth of vaccine responses in this vulnerable population.

Shapiro et al. 13

282	For measurement of functional antibodies, ACE2-inhibition assays are a strong surrogate of live
283	virus neutralization [24, 39]. In terms of responses to VOC, the reductions in anti-S IgG to the
284	Alpha and Delta variants observed in the older adults were similar to other reports in the
285	general population [40]. For the Omicron variant, while reductions in live-virus neutralization in
286	vaccinated serum from the general adult population have been reported, there were no
287	reductions in anti-Omicron S IgG [41, 42]. Given the importance of neutralizing and non-
288	neutralizing functions of IgG in conferring protection against SARS-CoV-2 [43, 44], the markedly
289	lower anti-Omicron S IgG level in older adults, that persisted after receipt of a third vaccine
290	dose, suggests that this population may be more vulnerable to disease caused by the Omicron
291	variant than younger adults, and that reformulation of vaccines to target the Omicron variant
292	would be beneficial.

293 Our study had several strengths and limitations. Some of the sex-specific effects 294 observed were differences among males that were absent among females, without statistical 295 evidence of a sex difference (i.e., non-significant sex interaction terms) [45]. It is important to 296 note that our findings were generated from *post-hoc* analyses that were not necessarily 297 powered to investigate sex differences, and conclusions are limited by small samples sizes in 298 certain sub-groups. Given the small sample sizes, it is not surprising that statistically significant 299 sex differences were not consistently observed. Particularly for age-based analyses, however, 300 the consistency of trends between assays and timepoints, coupled with statistically significant sex differences in the effect of aging at 3M PD2, lend credibility to the conclusion that the 301 effects of age on antiviral antibody responses are driven by males. Further supporting these 302 303 findings are similar sex-specific effects of age observed following seasonal influenza vaccination

Shapiro et al. 14

304	in both younger and older adults [17, 46]. While it is important to not over-interpret 'within-
305	sex' differences as 'between-sex' differences [47], there is considerable value in studying
306	differences within males or feamles [48, 49]. This is particularly true given the uniqueness of
307	the community-dwelling older adult cohort, which represent the 'oldest' old subset, and are
308	distinct from the population of long-term care facility residents that has been the focus of much
309	of the SARS-CoV-2 research in older adults.
310	There also were missing data in the older adult cohort, particularly at the <1M_PD1
311	timepoint. These missing data did not, however, depart from the missing at random
312	assumption, and thus multi-level models were used to account for missingness. Second, the
313	timing of sample collection was different in the older and younger cohorts. To account for this,
314	analyses that compared the two groups used days post-vaccination as a continuous variable.
315	Finally, we have not investigated the functional antibody responses to the Omicron variant, nor
316	have we included measures of cellular immunity. These analyses are on-going.
317	In conclusion, we report that both age and frailty impair antibody responses to the
318	primary series of SARS-CoV-2 vaccination in older males, and that these disparities are largely
319	eliminated by receipt of a third vaccine dose. Given that male sex is an important risk factor for
320	severe outcomes from COVID-19 [10-14], the finding that older and frail males may be
321	vulnerable to breakthrough infections due to low antibody responses, particularly before a
322	third vaccine dose is administered, is of considerable public health importance. These findings
323	emphasize that increasing third dose coverage among older males is crucial to protecting this
324	vulnerable population from SARS-CoV-2.

325

Shapiro et al. 15

326 Funding

- 327 This work was supported by the NIH/NIA Specialized Center of Research Excellence U54
- 328 AG062333 awarded to S.L.K. and the NIH/NCI COVID-19 Serology Center of Excellence (U54
- 329 CA260492 awarded to S.L.K. This work was also supported by funding from the Milstein Medical
- Asian American Partnership (MMAAP) Foundation of USA as well as Howard and Abby Milstein
- 331 Foundation awarded to S.X.L, and by the generosity of the collective community of donors to
- the Johns Hopkins University School of Medicine and the Johns Hopkins Health System for
- Covid-19 research. J.R.S was supported by a training award from the Fonds de recherche du
- 334 Québec Santé (File #287609).

335

336 Acknowledgements

- The authors thank the participants, as well as Denise C. Kelly and Eileen Sheridan-Malone for
- 338 collection of samples. The authors thank Emily Egbert for coordination of samples and
- 339 healthcare worker patients, and Joseph Shiloach, David Quan, and Yesh Muralidharan for

340 technical assistance.

341

342 <u>References</u>

- 1. Kang S-J, Jung SI. Age-related morbidity and mortality among patients with COVID-19.
- 344 Infection & chemotherapy **2020**; 52(2): 154.
- O'Driscoll M, Dos Santos GR, Wang L, et al. Age-specific mortality and immunity patterns
 of SARS-CoV-2. Nature **2021**; 590(7844): 140-5.
- Chen Y, Klein SL, Garibaldi BT, et al. Aging in COVID-19: Vulnerability, immunity and
 intervention. Ageing Res Rev **2020**: 101205.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid 19 vaccine. New England Journal of Medicine **2020**.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
 Vaccine. New England Journal of Medicine **2020**.

353	6.	Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence: A systems-
354		level overview of immune cell biology and strategies for improving vaccine responses.
355		Exp Gerontol 2019 ; 124: 110632.
356	7.	Abe KT, Hu Q, Mozafarihashjin M, et al. Neutralizing antibody responses to SARS-CoV-2
357		variants in vaccinated Ontario long-term care home residents and workers. medRxiv
358		2021 : 2021.08.06.21261721.
359	8.	Canaday DH, Carias L, Oyebanji O, et al. Reduced BNT162b2 mRNA vaccine response in
360		SARS-CoV-2-naive nursing home residents. medRxiv 2021.
361	9.	Causa R, Almagro-Nievas D, Rivera-Izquierdo M, et al. Antibody Response 3 Months
362		after 2 Doses of BNT162b2 mRNA COVID-19 Vaccine in Residents of Long-Term Care
363		Facilities. Gerontology 2021 : 1-7.
364	10.	Salje H, Kiem CT, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France.
365		Science 2020 ; 369(6500): 208-11.
366	11.	Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,
367		and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City
368		Area. JAMA 2020 ; 323(20): 2052-9.
369	12.	Meng Y, Wu P, Lu W, et al. Sex-specific clinical characteristics and prognosis of
370		coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe
371		patients. PLoS pathogens 2020 ; 16(4): e1008520.
372	13.	Bauer P, Brugger J, Koenig F, Posch M. An international comparison of age and sex
373		dependency of COVID-19 Deaths in 2020-a descriptive analysis. medRxiv 2021.
374	14.	Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex
375		impacts immune responses and COVID-19 outcomes. Nat Rev Immunol 2020: 1-6.
376	15.	Gubbels Bupp MR, Potluri T, Fink AL, Klein SL. The Confluence of Sex Hormones and
377		Aging on Immunity. Front Immunol 2018 ; 9: 1269.
378	16.	Márquez EJ, Chung C-h, Marches R, et al. Sexual-dimorphism in human immune system
379		aging. Nature communications 2020 ; 11(1): 1-17.
380	17.	Shapiro JR, Li H, Morgan R, et al. Sex-specific effects of aging on humoral immune
381		responses to repeated influenza vaccination in older adults. Npj Vaccines 2021; 6(1):
382		147.
383	18.	Bischof E, Wolfe J, Klein SL. Clinical trials for COVID-19 should include sex as a variable.
384		The Journal of Clinical Investigation 2020 ; 130(7).
385	19.	Shapiro JR, Morgan R, Leng SX, Klein SL. Roadmap for sex-responsive influenza and
386		COVID-19 vaccine research in older adults. Frontiers in Aging 2022 ; in press.
387	20.	Fried LP, Tangen CM, Walston J, et al. Frailty in Older Adults: Evidence for a Phenotype.
388		Journals Gerontology Ser Biological Sci Medical Sci 2001 ; 56(3): M146-M57.
389	21.	Zhong D, Xiao S, Debes AK, et al. Durability of Antibody Levels After Vaccination With
390		mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. JAMA 2021.
391	22.	Klein SL, Pekosz A, Park H-S, et al. Sex, age, and hospitalization drive antibody responses
392		in a COVID-19 convalescent plasma donor population. The Journal of Clinical
393		Investigation 2020.
394	23.	NCI Serological Sciences Network for COVID-19 (SeroNet). Available at:
395		https://www.cancer.gov/research/key-initiatives/covid-19/coronavirus-research-
396		initiatives/serological-sciences-network.

397	24.	Karaba AH, Zhu X, Liang T, et al. A Third Dose of SARS-CoV-2 Vaccine Increases
398		Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant
399		Recipients. American Journal of Transplantation 2021.
400	25.	Newson RB. Sensible parameters for univariate and multivariate splines. The Stata
401		Journal 2012 ; 12(3): 479-504.
402	26.	Kohler H. Novel vaccine concept based on back-boost effect in viral infection. Vaccine
403		2015 ; 33(29): 3274-5.
404	27.	Anderson EM, Eiloa T, Goodwin E, et al. SARS-CoV-2 infections elicit higher levels of
405		original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations.
406	28.	Grobben M, Straten Kvd, Brouwer PJM, et al. Cross-reactive antibodies after SARS-CoV-2
407		infection and vaccination. eLife 2021 ; 10: e70330.
408	29.	Bates TA, Leier HC, Lyski ZL, et al. Age-Dependent Neutralization of SARS-CoV-2 and P.1
409		Variant by Vaccine Immune Serum Samples. JAMA 2021 ; 326(9).
410	30.	Jabal KA, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection
411		status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19
412		vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January
413		2021. Eurosurveillance 2021 ; 26(6): 2100096.
414	31.	Collier DA, Ferreira IATM, Kotagiri P, et al. Age-related immune response heterogeneity
415		to SARS-CoV-2 vaccine BNT162b2. Nature 2021 ; 596(7872): 417-22.
416	32.	Wang J, Tong Y, Li D, Li J, Li Y. The Impact of Age Difference on the Efficacy and Safety of
417		COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol 2021 ; 12.
418	33.	Mwimanzi F, Lapointe H, Cheung PK, et al. Older Adults Mount Less Durable Humoral
419		Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial
420		Responses to a Third Dose, medRxiv 2022 .
421	34.	Ríos SS, Romero MM, Zamora EBC, et al. Immunogenicity of the BNT162b2 vaccine in
422		frail or disabled nursing home residents: COVID-A study. J Am Geriatr Soc 2021 : 69(6):
423		1441-7.
424	35.	Seiffert P. Konka A. Kasperczyk J. et al. Immunogenicity of the BNT162b2 mRNA COVID-
425		19 vaccine in older residents of a long-term care facility: relation with age, frailty and
426		prior infection status. Biogerontology 2021 .
427	36.	Demaret J. Corrover-Simovic B. Alidiinou EK. et al. Impaired Functional T-Cell Response
428		to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People. Front
429		Immunol 2021 : 12(4639).
430	37.	Hollinghurst L. North L. Perry M. et al. COVID-19 infection risk amongst 14,104
431	071	vaccinated care home residents: a national observational longitudinal cohort study in
432		Wales UK December 2020–March 2021 Age Ageing 2021
433	38	Antonelli M. Penfold RS. Merino L et al. Risk factors and disease profile of post-
433	50.	varcination SARS-CoV-2 infection in LIK users of the COVID Symptom Study and a
434		prospective community-based nested case-control study Lancet Infect Dis 2021
435	29	Tan CW. Chia W/N. Oin X. et al. A SARS-CoV-2 surrogate virus neutralization test based
430 127	55.	on antibody-mediated blockage of $\Delta CF2$ -snike protein-protein interaction. Not
437 128		Biotechnol 2020 : 38(9): 1073-8
730 730	40	Goldblatt D. Fiore-Gartland A. Johnson M. et al. Towards a nonulation-based threshold
775 710	4 0.	of protection for COVID-19 vaccines Vaccine 2021
440		of protection for $COVID^{-13}$ values. Value 2021 .

Shapiro et al. 18

441 442	41.	Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 2021 .
443 444	42.	Bartsch Y, Tong X, Kang J, et al. Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms, medRxiv 2021 .
445	43.	Chan CEZ. Seah SGK. Chve DH. et al. The Fc-mediated effector functions of a potent
446		SARS-CoV-2 neutralizing antibody. SC31, isolated from an early convalescent COVID-19
447		patient, are essential for the optimal therapeutic efficacy of the antibody. Plos One
448		2021 ; 16(6): e0253487.
449	44.	Gorman MJ, Patel N, Guebre-Xabier M, et al. Fab and Fc contribute to maximal
450		protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M
451		vaccination. Cell Reports Medicine 2021 ; 2(9).
452	45.	Vorland CJ. Statistics: Sex difference analyses under scrutiny. Elife 2021 ; 10: e74135.
453	46.	Kuo H, Shapiro JR, Dhakal S, et al. Sex-specific effects of age and body mass index on
454		antibody responses to seasonal influenza vaccines in healthcare workers. Vaccine 2021.
455	47.	Shattuck-Heidorn H, Danielsen AC, Gompers A, et al. A finding of sex similarities rather
456		than differences in COVID-19 outcomes. Nature 2021 ; 597(7877): E7-E9.
457	48.	Shapiro JR, Klein SL, Morgan R. Stop 'controlling' for sex and gender in global health
458		research. Bmj Global Heal 2021 ; 6(4): e005714.
459	49.	Shapiro JR, Klein SL, Morgan R. COVID-19: use intersectional analyses to close gaps in
460		outcomes and vaccination. Nature 2021 ; 591(7849): 202.
461		

462

Shapiro et al. 19

463 **Tables**

464 Table 1. Older adult participant characteristics

	All	Male	Female
Included in analysis - n (%) ^a	82	34 (41)	48 (59)
Recruited - n	86	34	52
Excluded - n ^b	4	0	4
Age - median (IQR)	84 (81 - 88)	84 (82 - 88)	83 (81 - 89)
Categories - n (%) ^c			
75-82	32 (39)	12 (35)	20 (42)
83-87	28 (34)	13 (38)	15 (31)
88-98	22 (27)	9 (26)	13 (27)
Frailty - n (%) ^c			
Robust	18 (22)	8 (24)	10 (21)
Pre-frail	53 (64)	20 (59)	33 (67)
Frail	10 (12)	6 (18)	4 (8)
Missing	1 (1)	0 (0)	1 (2)
Vaccine type - n (%)°			
mRNA-1273 (Moderna)	24 (30)	8 (24)	16 (33)
BNT162b2 (Pfizer)	58 (70)	26 (76)	32 (67)
Visit participation - n (%) ^{c,d}			
Pre	82 (100)	34 (100)	48 (100)
<1M_PD1	23 (28)	11 (32)	12 (25)
<1M_PD2	69 (84)	28 (82)	41 (85)
3M_PD2	82 (100)	34 (100)	48 (100)
6M_PD2	80 (98)	33 (97)	47 (98)
1M_PD3	60 (73)	26 (76)	34 (71)

^a Subset of eligible participants without evidence of prior infection who were included in analysis

^b Participants with high (> 1:180) nucleocapsid titers, indicating prior infection, were excluded from analysis. One additional participant was excluded due to evidence of severe immunesuppression

^c Percents are based on the number included in analysis in each column

^d Study timepoints: Pre-vaccination (Pre); 14-30 days post dose 1 (<1M_PD1); 14-30 days post dose 2 (<1M_PD2); 75-105 days post dose 1 (3M_PD2); 165-195 days post dose 1 (6M_PD2); 75-105 days post dose 1 (3M_PD2); 14-60 days post dose 3 (1M_PD3)

Shapiro et al. 20

466 Table 2. Younger adult participant characteristics

	All	Male	Female
Included in analysis - n (%) ^a	81	32 (40)	49 (60)
Eligible - n ^b	84	32	52
Excluded - n ^c	3	0	3
Age at vaccination - n (%) ^d			
≤29	14 (17)	4 (12)	10 (20)
30-39	32 (40)	11 (34)	21 (43)
40-49	18 (22)	8 (25)	10 (20)
50-59	7 (9)	4 (13)	3 (6)
60-74	10 (12)	5 (16)	5 (10)
Sample 1 - days post dose 2			
Mean (min-max)	33 (16-76)	31 (16-65)	34 (16-76)
Median (IQR)	29 (21-43)	27 (21-41)	29 (21-43)
Sample 2 - days post dose 2			
Mean (min-max)	138 (96-190)	142 (110 - 190)	136 (96-183)
Median (IQR)	137 (125-150)	139 (128-156)	137 (123-147)

^a Subset of eligible participants without evidence of prior infection who were included in analysis

^b Eligible participants from affiliated study (ref) were <75 years of age, had remaining serum from 2 samples collected at least 90 days apart 14-200 days following 2 doses of an mRNA SARS-CoV-2 vaccine who did not report prior SARS-CoV-2 infection

^c Participants with high (> 1:180) nucleocapsid titers, indicating prior infection, were excluded from analysis

^d Percents are based on the number included in analysis in each column

467

Shapiro et al. 21

468 Figure Legends

Figure 1. Older females mount greater humoral responses to SARS-CoV-2 mRNA vaccines than older males.

- 471 Anti-spike (S) IgG (A), S receptor-binding domain (S-RBD) IgG (B), and ACE2-inhibiting antibodies
- 472 (ACE2iAb) (C) against the vaccine strain of SARS-CoV-2 were measured at six timepoints: pre-
- 473 vaccination (n= 82: 48 females, n = 34 males), 14-30 days post dose 1 (<1M_PD1; n=23: 12
- 474 females, 11 males), 14-30 days post dose 2 (<1M_PD2; n=69: 41 females, 28 males), 3 months
- 475 post dose 2 (3M_PD2; n=82: 48 females, 34 males), 6 months post dose 2 (6M_PD2; n=80: 47
- 476 females, 33 males), and 14-30 days post dose 3 (1M_PD1; n=60: 34 females, 26 males).
- 477 Differences between timepoints were tested using mixed-effects models with study timepoint
- 478 as a dummy variable and random intercepts on the individual. Sex differences were tested
- using an expanded mixed-effects model that included a main effect for sex and an interaction
- 480 term between sex and study timepoint. All point estimates are shown with error bars indicating
- 481 the 95% confidence interval. All p-values <0.05 are reported in **D**, where blank cells indicate a p-
- 482 value >0.05 and crossed out cells indicate that the comparison is reported elsewhere in the
- 483 table. Dashed lines show the limits of detection.
- 484

Figure 2. Age and frailty impact the antibody response to SARS-CoV-2 mRNA vaccines in a sex specific manner among older adults.

- 487 The effect of age on antibody kinetics is shown for Anti-spike (S) IgG (A), S receptor-binding
- 488 domain (S-RBD) IgG (**B**), and ACE2-inhibiting antibodies (ACE2iAb) (**C**) against the vaccine strain
- 489 of SARS-CoV-2. Data are shown for six timepoints: pre-vaccination (n=32 aged 75-82; n=28 aged

490	83-87; n=22 aged ≥88), <1M_PD1 (n=10 aged 75-82; n=8 aged 83-87; n = 5 aged ≥88), <1M_PD2
491	(n=24 aged 75-82; n=25 aged 83-87; n=20 aged ≥88), 3M_DP2 (n=32 aged 75-82; n=28 aged 83-
492	87; n=22 aged ≥88), 6M_PD2 (n=31 aged 75-82; n=28 aged 83-87; n=21 aged ≥88), and 1M_PD3
493	(n=22 aged 75-82; n=21 aged 83-87; n=17 aged ≥88) (A-C). Sex-specific effects of age at
494	3M_PD2 are shown separately for females (n=20 aged 75-82; n=15 aged 83-87; n=13 aged ≥88)
495	and males (n=12 aged 75-82; n=13 aged 83-87; n=9 aged ≥88) (D-F). The effect of frailty on
496	antibody kinetics is shown for the three assays at six timepoints: pre-vaccination (n=18 robust;
497	n=53 pre-frail; n=10 frail), <1M_PD1 (n=6 robust; n=12 pre-frail; n=5 frail), <1M_PD2 (n=15
498	robust; n=45 pre-frail; n=9 frail), 3M_PD2 (n=18 robust; n=53 pre-frail; n=10 frail), 6M_PD2
499	(n=18 robust; n=52 pre-frail; n=10 frail), and 1M_PD3 (n=14 robust; n=39 pre-frail; n=7 frail) (G-
500	I). are shown separately for females (n=10 robust; n=33 pre-frail; n=4 frail) and males (n=8
501	robust; n=20 pre-frail; n=6 frail) (J-L). The overall effects of age (A-C) or frailty (H-I) at each
502	timepoint were tested using mixed-effects models including a main effect for age/frailty, an
503	interaction term between age/frailty and study timepoint, and all p-values <0.05 are shown. At
504	3M_PD2, the effect of age (D-F) or frailty (J-L) in males and females, and sex-differences in
505	these effects, were tested using linear regression models with interaction terms between sex
506	and age or frailty, and all p-values are shown. Point estimates are shown with 95% confidence
507	intervals, and dashed lines indicate the limit of detection.
508	

509	Figure 3. Antibody responses to Alpha, Delta, and Omicron variants are reduced relative to
510	the vaccine virus in older adults.
511	Anti-S (A), and ACE2-inhibiting (B) antibodies against the vaccine, Alpha and Delta strains of
512	SARS-CoV-2 were measured post-vaccination, with symbols indicating point estimates and error
513	bars indicating the 95% confidence interval. Differences in the responses between viral strains
514	were measured using paired t-tests, and all p-values <0.05 are shown in C , where empty cells
515	indicate p-value>0.05 and crossed-out cells indicate that the comparison was not tested. Sex-
516	disaggregated data from the 3-month timepoint are shown, and significant sex differences are
517	indicated by p-values (D-E).
518	
519	Figure 4. Antibody responses against seasonal and pandemic β -coronaviruses are boosted by
520	SARS-CoV-2 vaccination in older adults.
520 521	SARS-CoV-2 vaccination in older adults. IgG specific to the spike proteins of the HKU1 (A), OC43 (B), MERS-CoV (C), and SARS-CoV-1 (D)
520 521 522	SARS-CoV-2 vaccination in older adults. IgG specific to the spike proteins of the HKU1 (A), OC43 (B), MERS-CoV (C), and SARS-CoV-1 (D) were measured before and at five timepoints after receipt of a SARS-CoV-2 mRNA vaccine.
520 521 522 523	SARS-CoV-2 vaccination in older adults. IgG specific to the spike proteins of the HKU1 (A), OC43 (B), MERS-CoV (C), and SARS-CoV-1 (D) were measured before and at five timepoints after receipt of a SARS-CoV-2 mRNA vaccine. Differences between timepoints were tested using multi-level models with study timepoint as a
520 521 522 523 524	SARS-CoV-2 vaccination in older adults. IgG specific to the spike proteins of the HKU1 (A), OC43 (B), MERS-CoV (C), and SARS-CoV-1 (D) were measured before and at five timepoints after receipt of a SARS-CoV-2 mRNA vaccine. Differences between timepoints were tested using multi-level models with study timepoint as a dummy variable and random intercepts on the individual to account for repeat measures. All
520 521 522 523 524 525	SARS-CoV-2 vaccination in older adults. IgG specific to the spike proteins of the HKU1 (A), OC43 (B), MERS-CoV (C), and SARS-CoV-1 (D) were measured before and at five timepoints after receipt of a SARS-CoV-2 mRNA vaccine. Differences between timepoints were tested using multi-level models with study timepoint as a dummy variable and random intercepts on the individual to account for repeat measures. All point estimates are shown with error bars indicating the 95% confidence interval and asterisks
520 521 522 523 524 525 526	SARS-CoV-2 vaccination in older adults. IgG specific to the spike proteins of the HKU1 (A), OC43 (B), MERS-CoV (C), and SARS-CoV-1 (D) were measured before and at five timepoints after receipt of a SARS-CoV-2 mRNA vaccine. Differences between timepoints were tested using multi-level models with study timepoint as a dummy variable and random intercepts on the individual to account for repeat measures. All point estimates are shown with error bars indicating the 95% confidence interval and asterisks indicate significant (p<0.05) increases relative to the pre-vaccination vaccination timepoint.

Shapiro et al. 24

Figure 5. Differences between younger and older adults in antibody responses to the vaccine strain of SARS-CoV-2 are sex-dependent.

530	Plasma samples were collected from older adults at 3 timepoints after the primary vaccination
531	series and from younger adults at 2 post-vaccination timepoints: 16-76 days post dose 2 (early)
532	and 96-190 days post dose 2 (late). Differences in anti-vaccine strain S IgG levels over time were
533	compared between all younger and older adults (A), males (younger: n=27 early; n=30 late) (B),
534	and females (younger: n=48 early; n=48 late) (C), and summarized at three sentinel points (14-,
535	90- and 180-days post-vaccination) (D). Comparisons of the anti-Alpha S IgG response between
536	the younger and older groups are shown for the whole population (E), males (younger: n=27
537	early; n=26 late) (F), and females (younger: n=39 early; n=34 late) (G), with differences
538	summarized at 14-, 90- and 180-days post-dose 2 (H). Comparisons of the anti-Delta S IgG
539	response between the younger and older groups are shown for the whole population (I), males
540	(younger: n=27 early; n=26 late) (J), and females (younger: n=47 early; n=42 late) (K), with
541	differences at summarized 14-, 90- and 180-days post-dose 2 (L). Kinetics were analyzed using
542	mixed-effects models with fixed effects including days post-dose 2 as a continuous predictor
543	with cubic B-splines (knots at 30-, 100-, and 160-days post-vaccination). Shaded areas indicate
544	95% confidence intervals (A-C, E-G, I-K). In D, H, and L, point estimates for the difference
545	between cohorts are shown with 95% confidence intervals, such that confidence intervals that
546	do not span the null value of zero are statistically significant.



			S-RBD IgG (B)					ACE2 inhibition (C)							
Significant difference between:	<1M_PD1	<1M_PD2	3M_PD2	6M_PD2	<1M_PD3	<1M_PD1	<1M_PD2	3M_PD2	6M_PD2	<1M_PD3	<1M_PD1	<1M_PD2	3M_PD2	6M_PD2	<1M_PD3
Visit & baseline	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Visit & <1M_PD2	<0.001		<0.001	<0.001	<0.001	<0.001		<0.001	<0.001	<0.001	<0.001		<0.001	<0.001	<0.001
Visit & previous visit	\sim			<0.001	<0.001			\langle	<0.001	<0.001	\sim			<0.001	<0.001
Sexes at visit	0.020		0.026										0.046		
Sexes in change since baseline	0.002	0.008	0.001	0.007	0.048	0.013	0.001	0.000	0.000	0.014					

D



medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272269; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





			S IgG (A)			ACE2iAb (B)					
Difference between:	<1M_PD1	<1M_PD2	3M_PD2	6M_PD2	1M_PD3	<1M_PD1	<1M_PD2	3M_PD2	6M_PD2	1M_PD3	
Vaccine & Alpha	<0.001	<0.001	<0.001	<0.001	<0.001		<0.001		0.026		
Vaccine & Delta	<0.001	<0.001	<0.001	<0.001	<0.001	0.002	0.005		0.010	0.050	
Vaccine & Omicron	<0.001	<0.001	<0.001	<0.001	<0.001			\backslash			
Alpha & Delta					<0.001	0.000		0.000			
Alpha & Omicron	<0.001	<0.001	<0.001	<0.001	<0.001						
Delta & Omicron	<0.001	<0.001	<0.001	<0.001	<0.001						

◆Vaccine ●Alpha ◆Delta ◆Omicron

Female

Male



medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272269; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

